Meta-analysis of fluoroquinolone antibiotics in the treatment of pelvic inflammatory disease and associated risk factors
Abstract
Pelvic inflammatory disease (PID) is a common infectious disease affecting the female reproductive organs and surrounding tissues. Antibiotics remain a cornerstone of current treatment regimens. This work aimed to systematically assess efficacy of fluoroquinolone antibiotics in the treatment of PID through meta-analysis (MA). Randomized controlled trials (RCTs) on fluoroquinolone antibiotics for uncomplicated PID were retrieved from online databases up to July 8, 2024. Statistical analysis was conducted using RevMan5.2, focusing on WBC count, CRP levels, clinical efficacy, and adverse reactions (ARs), with outcomes measured by odds ratios (ORs) and 95% confidence intervals (CIs). Fourteen studies were included, comprising a total of 2483 patients with PID, of whom 1244 received fluoroquinolone antibiotics (experimental group - EG). All patients received treatment for 7 to 14 days. After treatment, the EG showed significantly lower WBC and CRP levels compared to the control group (CG), with both differences statistically significant (P < .00001, 5 studies; I2 = 0% for WBC; I2 = 0% for CRP). The cure rate in EG was 66.43% (663/998), which was higher than the CG cure rate of 62.42% (623/998) (P < .05, 9 studies; I2 = 42%). The incidence rates of abdominal pain (3.89%, 18/463), nausea and vomiting (17.13%, 168/981), and overall adverse reactions (35.22%, 273/775) were all lower in EG compared to CG (P < .05, 7 studies for ARs; I2 = 54%). Fluoroquinolone antibiotics appear to…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 2,483 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.